http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Permeable tube를 利用한 toluene gas의 生物學的 處理에 관한 硏究
임경택,강신묵,곽영규 동아대학교 환경문제연구소 1989 硏究報告 Vol.12 No.2
Toluene gas was introduced into municipal waste water treatment plant's recycled sludge using permeable silicon tube. Bacterial strain was developed at the outside of tube. Toluene gas was removed by the microorganism with the removal efficiency being over 98% at the flow ate of 30㎖~180㎖/min, loading of 2,000ppm~2,560ppm and temperature 30℃. Sample taken from the sludge solution was analyzed by spectrophotometry and GC/Mass. Benzoic acid was found to prove bio-oxidation of toluene.
Lim, Youn-Mook,Lee, Young-Moo,Nho, Young-Chang The Polymer Society of Korea 2005 Macromolecular Research Vol.13 No.4
pH-sensitive hydrogels were studied as a drug carrier for the protection of insulin from the acidic environment of the stomach before releasing it in the small intestine. In this study, hydrogels based on poly(ethylene oxide) (PEO) networks grafted with methacrylic acid (MAA) or acrylic acid (AAc) were prepared via a two-step process. PEO hydrogels were prepared by ${\gamma}-ray $ irradiation (radiation dose: 50 kGy, dose rate: 7.66 kGy/h), grafted by either MAA or AAc monomers onto the PEO hydrogels and finally underwent irradiation (radiation dose: 520 kGy, dose rate: 2.15 kGy/h). These grafted hydrogels showed a pH-sensitive swelling behavior. The grafted hydrogels were used as a carrier for the drug delivery systems for the controlled release of insulin. Drug-loaded hydrogels were placed in simulated gastric fluid (SGF, pH 1.2) for 2 hr and then in simulated intestinal fluid (SIF, pH 6.8). The in vitro drug release behaviors of these hydrogels were examined by quantification analysis with a UV-Vis spectrophotometer.
Lim, Youn Mook,Lee, Jun Ho,Lee, Young Moo,Nho, Young Chang 한국공업화학회 2003 응용화학 Vol.7 No.2
pH-sensitive hydrogels were studied as a drug carrier for the protection of insulin from the acidic environment of the stomach before releasing it in the small intestine. In this study, hydrogels based on polyvinylpyrrolidone(PVP) networks grafted with acrylic acid (Ac) was prepared via a two-step process. PVP hydrogels were prepared by γ-ray irradiation (radiation dose: 25kGy, does rate: 5.36kGy/h), and then grafting by AAc monomers onto the PVP hydrogels with subsequent irradiation(radiation dose: 10kGy, dose rate: 3.0kGy/h). These grafted hydrogels showed a pH-sensitive swelling behavior in various pH.
Effect of electron beam irradiation on poly(vinylidene fluoride) films at the melting temperature /
Lim, Youn Mook,Kang, Phil Hyun,Lee, Sang Mann,Kim, Sung Sik,Jeun, Joon Pyo,Jung, Chan Hee,Choi, Jae Hak,Lee, Young Moo,Nho, Young Chang The Korean Society of Industrial and Engineering C 2006 Journal of industrial and engineering chemistry Vol.12 No.4
Properties of Conductive Poly(ethylene oxide) (PEO) / Carbon Black (CB) Composite as a Vapor Sensor
Lim, Youn Mook,Kang, Phil Hyun,Lee, Young Moo,Nho, Young Chang 한국공업화학회 2004 Journal of Industrial and Engineering Chemistry Vol.10 No.2
We have investigated the effect of solvent and carbon black structure on the electric resistance of the vapor sensor composite materials prepared by dispersing carbon black (CB) into a poly(ethy1ene oxide) (PEO) matrix. PEO polymers having molecular weights of 2 ×10^(6) and 4 ×10^(6) were selected to be the polar crystalline polymers. Carbon black, with particle sizes ranging from 45 to 300 nm, was used as a conductive material. After PEO was dissolved completely in tetrahydrofuran at 5O℃, CB was added and stirred into the polymer solution uniformly. A conductive PEO film containing CB was made by casting it on a glass plate. The electrical resistance of the conductive PEO film in various solvent vapors, such as acetone, benzene, ethanol, isopropyl alcohol, and tetrahydrofuran, was measured in a glass tube containing pure solvent at the bottom. We found that the electrical resistance of the PEO/CB composite increased drastically in polar-solvent vapor, but had a low response to a non- and low-polar-solvent vapor. A PEO film filled with CB of large particle size exhibited a high response of its electrical resistance against vapors.
( Won-mook Choi ),( Jonggi Choi ),( Danbi Lee ),( Ju Hyun Shim ),( Young-suk Lim ),( Han Chu Lee ),( Young-hwa Chung ),( Young-sang Lee ),( Sook Ryun Park ),( Min-hee Ryu ),( Baek-yeol Ryoo ),( So Jun 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Regorafenib and nivolumab are drugs approved for second-line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. Methods: This study retrospectively evaluated 373 patients with HCC who were treated with regorafenib (n=223) or nivolumab (n=150) after sorafenib failure between July 2017 and February 2019. Results: Progression-free survival (PFS; hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.69-1.06; P=0.150), time to progression (TTP; HR, 0.95; 95% CI, 0.77-1.19; P=0.680), and overall survival (OS; HR, 0.83; 95% CI, 0.64-1.07; P=0.154) did not differ significantly between groups of patients treated with regorafenib and nivolumab, findings consistently observed by multivariable-adjusted, propensity score-matched, and inverse probability treatment weighting (IPTW) analyses. However, the objective response rate was significantly higher in the nivolumab than in the regorafenib group (13.3% vs, 4.0%; P=0.002). When the effectiveness of regorafenib and nivolumab was compared in non-progressors to treatment, defined as patients who achieved complete response, partial response, or stable disease after first response evaluation, PFS (HR, 0.50; 95% CI, 0.33-0.75; P=0.001), TTP (HR, 0.48; 95% CI, 0.31-0.73; P<0.001), and OS (HR, 0.51; 95% CI, 0.31-0.87; P=0.013) were significantly longer in the 59 non-progressors to nivolumab than in the 104 non-progressors to regorafenib, findings also observed by multivariable-adjusted and IPTW analyses. Conclusions: Survival outcomes in patients treated with regorafenib and nivolumab after sorafenib failure did not differ significantly. However, nivolumab may be more effective than regorafenib in non-progressors.